Leonardo D Borregales1, Gina DeMeo1, Xiangmei Gu2, Emily Cheng1, Vanessa Dudley1, Edward M Schaeffer3, Himanshu Nagar4, Sigrid Carlsson5,6,7, Andrew Vickers6, Jim C Hu1. 1. Department of Urology, Weill Cornell Medicine/New York-Presbyterian, New York, NY, USA. 2. Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA. 3. Department of Urology, Northwestern University, Chicago, IL, USA. 4. Department of Radiation Oncology, Weill Cornell Medicine/New York-Presbyterian, New York, NY, USA. 5. Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Institute of Clinical Sciences, Department of Urology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Abstract
BACKGROUND: Prostate cancer (PC) screening guidelines have changed over the last decade to reduce overdiagnosis and overtreatment of low-grade disease. We sought to examine and attempt to explain how changes in screening strategies have impacted temporal trends in Gleason grade group (GG) PC at diagnosis and radical prostatectomy pathology. METHODS: Using the Surveillance, Epidemiology, and End Results Registry database, we identified 438 432 men with newly diagnosed PC during 2010-2018. Temporal trends in incidence of GG at biopsy, radical prostatectomy pathology, prostate-specific antigen (PSA) level, and metastasis at diagnosis were examined. The National Health Interview Survey database was examined to evaluate trends in PSA-screening rates, and a literature review evaluating magnetic resonance imaging and biomarkers utilization during this period was performed. RESULTS: Between 2010 and 2018, the incidence of low-grade PC (GG1) decreased from 52 to 26 cases per 100 000 (P < .001). The incidence of GG1 as a proportion of all PC decreased from 47% to 32%, and the proportion of GG1 at radical prostatectomy pathology decreased from 32% to 10% (P < .001). However, metastases at diagnosis increased from 3.0% to 5.2% (P < .001). During 2010-2013, PSA screening rates in men aged 50-74 years declined from 39 to 32 per 100 men and remained stable. Utilization rates of magnetic resonance imaging and biomarkers modestly increased from 7.2% in 2012 to 17% in 2019 and 1.3% in 2012 to 13% in 2019, respectively. CONCLUSIONS: We found a significant decrease in the diagnosis and treatment of GG1 PC between 2010 and 2018. Changes in PSA screening practices appear as the primary contributor. Public health efforts should be directed toward addressing the increase in the diagnoses of metastatic PC.
BACKGROUND: Prostate cancer (PC) screening guidelines have changed over the last decade to reduce overdiagnosis and overtreatment of low-grade disease. We sought to examine and attempt to explain how changes in screening strategies have impacted temporal trends in Gleason grade group (GG) PC at diagnosis and radical prostatectomy pathology. METHODS: Using the Surveillance, Epidemiology, and End Results Registry database, we identified 438 432 men with newly diagnosed PC during 2010-2018. Temporal trends in incidence of GG at biopsy, radical prostatectomy pathology, prostate-specific antigen (PSA) level, and metastasis at diagnosis were examined. The National Health Interview Survey database was examined to evaluate trends in PSA-screening rates, and a literature review evaluating magnetic resonance imaging and biomarkers utilization during this period was performed. RESULTS: Between 2010 and 2018, the incidence of low-grade PC (GG1) decreased from 52 to 26 cases per 100 000 (P < .001). The incidence of GG1 as a proportion of all PC decreased from 47% to 32%, and the proportion of GG1 at radical prostatectomy pathology decreased from 32% to 10% (P < .001). However, metastases at diagnosis increased from 3.0% to 5.2% (P < .001). During 2010-2013, PSA screening rates in men aged 50-74 years declined from 39 to 32 per 100 men and remained stable. Utilization rates of magnetic resonance imaging and biomarkers modestly increased from 7.2% in 2012 to 17% in 2019 and 1.3% in 2012 to 13% in 2019, respectively. CONCLUSIONS: We found a significant decrease in the diagnosis and treatment of GG1 PC between 2010 and 2018. Changes in PSA screening practices appear as the primary contributor. Public health efforts should be directed toward addressing the increase in the diagnoses of metastatic PC.
Authors: Jim C Hu; Paul Nguyen; Jialin Mao; Joshua Halpern; Jonathan Shoag; Jason D Wright; Art Sedrakyan Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Andrew B Rosenkrantz; Jennifer Hemingway; Danny R Hughes; Richard Duszak; Bibb Allen; Jeffrey C Weinreb Journal: J Urol Date: 2018-02-02 Impact factor: 7.450
Authors: Claire M de la Calle; Vittorio Fasulo; Janet E Cowan; Peter E Lonergan; Martina Maggi; Adam J Gadzinski; Reuben Au Yeung; Alberto Saita; Matthew R Cooperberg; Katsuto Shinohara; Peter R Carroll; Hao G Nguyen Journal: J Urol Date: 2020-09-08 Impact factor: 7.450
Authors: Wen Liu; Dattatraya Patil; David H Howard; Renee H Moore; Heqiong Wang; Martin G Sanda; Christopher P Filson Journal: Urology Date: 2018-04-18 Impact factor: 2.649
Authors: Richard M Hoffman; Sarah L Mott; Bradley D McDowell; Sonia T Anand; Kenneth G Nepple Journal: Prostate Cancer Prostatic Dis Date: 2021-06-09 Impact factor: 5.455